

EOM IG – CMS 07 FHIR Connectathon 6 Kick Off

www.globalalliantinc.com



- Enhancing Oncology Model (EOM) Use Case
 - Overview
 - Timeline & Current State
 - Project team
- EOM Implementation Guide (IG)
 - Test Scenarios & Testing Goals
 - Testing Access
- Useful Links
- Questions

Overview

- Purpose:
 - Test the Center for Medicare and Medicaid Innovation (CMMI) Enhancing Oncology Model Implementation
 Guide (EOM IG) for the collection and reporting of clinical data for specific cancer types as part of the strategic
 goals of EOM.
- Context:
 - EOM is designed to promote patient-centered care
 - EOM focuses on:
 - supporting patients, caregivers, and survivors,
 - learning from all patients, and
 - targeting the right treatments for the right patients.

Overview

- EOM is a CMMI (Innovation Center) alternative payment model designed to promote high quality, person-centered care, encourage better care coordination, improve access to care, reduce costs, and improve outcomes for Medicare fee-for-service (FFS) beneficiaries with cancer who receive cancer treatment.
- EOM builds on lessons from the Oncology Care Model (OCM) and shares certain features with OCM.
- EOM participants are oncology Physician Group Practices (PGPs) that prescribe and administer chemotherapy for cancer.
- The model is centered on 6-month episodes of care triggered by receipt of a qualifying initiating cancer therapy for an included cancer type. The model includes seven cancer types:
 - Breast Cancer
 - Chronic Leukemia
 - Lung Cancer
 - Lymphoma
 - Multiple Myeloma
 - Prostate Cancer
 - Small Intestine/Colorectal Cancer



Timeline & Current State

- EOM started in July 2023; Cohort 2 begins July 2025; Model extended through 2030
- EOM is targeting collecting Sociodemographic Data Elements (SDEs) and Clinical Data Elements (CDEs) for Performance Period (PP) 3 and PP1 True-Up in Fall 2025
 - Data collection will be available via "low tech" and "high tech" options through the CMMI Innovation Support Platform (ISP)
 - FHIR-based API submissions will be available using the EOM IG, which is conformant with the Minimal Common Oncology Data Elements (mCODE) standard
- The EOM IG has evolved based on our previous Connectathon testing and the contributions of our EOM community.
 - Primary Tumor, Nodal Disease, Metastasis small number of code updates
 - Additional HER2 Test Specified code allowed (104279-5)
 - Requirements for reporting have been waived for a subset of SDEs

Project Team

Global Alliant:

- Denise St. Clair Denise.s@globalalliantinc.com
- Jansi Mohan Jansi.m@globalalliantinc.com
- Prakash Gadepalli <u>prakash.g@globalalliantinc.com</u>
- Jessica Skopac <u>jessica.s@globalalliantinc.com</u>

EOM Model Team:

Priya Chatterjee, Batsheva Honig, Claire Kihn

ONC: Liz Turi Liz.Turi@hhs.gov

Special thanks for support from the EOM Implementation & Monitoring team, Will Gordon (CMMI), the Firely Team, the MITRE mCODE and CodeX teams, Next Level Health Innovation, and the Assistant Secretary for Technology Policy (ASTP)/Office of the National Coordinator (ONC) USCDI + Cancer team for their leadership.



Test Scenarios & Testing Goals

Scenario 1: ISP Query

 Action: Reporting System started will query the ISP test system to retrieve roster (Medicare Beneficiary Identifier (MBI) attribution list) information and associated defined data elements, including EOM episode dates, to support retrieving the appropriate data to include in the test FHIR payload (Parameters Resource)

Scenario 2: The Reporting System initiates the submission of a test FHIR bundle to the Receiving System

- Action: Create and Send EOM IG test bundle for one or more MBIs.
- Success Criteria #1: Confirm successful receipt by Receiving System.
- Success Criteria #2: Confirm acknowledgement of receipt by Submission System

Scenario 3: The Recipient System consumes the received EOM IG bundle and validates data

- Action: Receive and validate EOM IG bundle (receipt of bundle and validation)
 - Sends an Acknowledgement (ACK) to Reporting System
 - Consumes data and confirms data meets reporting requirements



Tuesday, July 15

- 1:30-2:30 pm ET EOM IG Track Kick Off & Overview
- 2:30-4:30 pm ET EOM IG Testing
- 4:30-5pm ET EOM IG Testing Debrief

Wednesday, July 16

- 10am 12pm ET EOM IG Testing
- 12-12:30pm ET EOM IG Testing Check-In
- 1:30pm 4pm ET EOM IG Testing
- 4pm-5pm EOM IG Testing Debrief

Thursday, July 17

- 11:30-1pm ET EOM IG Office Hours (end points open for testing all day)
- 2:20-2:40pm EOM IG Track Highlights

Test Access

- Provide tester first name, last name, and email address to the Global Alliant ISP team
- Through this email, testers will receive:
 - Details about the API endpoints
 - API key (access token) to access those API endpoints
 - The Entity ID assigned to the participant and test data
- To test the ability to query for patient population information (aka "prefill data")
 - Tester will need to share via API request
 - Authorization token (API Key shared via email)
 - Query String Parameters = entityId=EOM-PGP-XXXX
 - Response will be a Parameters Resource for each attributed beneficiary and include
 - MBI
 - First and Last names
 - Date of birth
 - Administrative gender
 - Attributed Cancer type
 - Episode start and end dates



Useful Links

- EOM Connectathon Track Page: https://confluence.hl7.org/spaces/FHIR/pages/345538790/2025+-+07+Enhancing+Oncology+Model+EOM+Implementation+Guide
- EOM Zulip Stream: https://chat.fhir.org/#narrow/stream/428252-Enhancing-Oncology-Model-.28EOM.29-IG/
- EOM IG: https://simplifier.net/guide/enhancing-oncology-model/Home?version=1.0.1
- Model overview and more information: https://www.cms.gov/priorities/innovation/innovation-models/enhancing-oncology-model
- EOM Clinical Data Elements Guide v2.3: https://www.cms.gov/priorities/innovation/media/document/eom-clinical-data-elements-guide

Questions?

THANK YOU!



Denise St Clair, PhD (Main Contact)
Vice President, Health Policy & Interoperability
denise.s@globalalliantinc.com